biotechnology stocks

The bottom half of December will prove to be a busy one for the biotechnology sector. Below are six biotech companies with catalysts still ahead for the end of the year. Roche Holding Roche Holding Ltd. (ADR) (OTC: RHHBY)'s Genentech unit's OCREVUS's Prescription Drug User Fee Act (PDUFA) date is...

Allergan plc Ordinary Shares (NYSE: AGN) paid a hefty premium of 159 percent to acquire Vitae Pharmaceuticals Inc (NASDAQ: VTAE) last week, but that figure pales in comparison to the premium attached to its acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA). Allergan will pay $533 million in...

Juno Therapeutics Inc (NASDAQ: JUNO) announced late Thursday it has received notice from the U.S. Food and Drug Administration that it has placed a clinical hold on its Phase II clinical trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. The trial,...

Slingshot Insights, a crowdfunded expert network that offers investment research tools, conducted an expert call on Moleculin Biotech Inc (NASDAQ: MBRX) AML drug Annamycin last Friday. The goal of the call was to offer investors the opportunity to better understand how the drug differs from...

Shares of bluebird bio Inc (NASDAQ: BLUE) were trading lower by 5 percent mid-Thursday afternoon after the company reported its first-quarter results. Bluebird bio said that it lost $1.52 per share on revenue of $1.499 million during the quarter. Wall Street analysts were expecting the company to...

The Street Sweeper's Sonya Colberg published a scathing short thesis on Bio-Path Holdings Inc (NASDAQ: BPTH), a clinical-stage biotechnology company that focuses on developing drugs to fight cancer. Colberg's main criticism of the company is the fact that it "spent six years...

Short interest can be a very telling component of investor and trader sentiment toward a stock. High or rising short interest typically means that investors and traders believe a stock is going to drop or continue a current decline further. However, high short interest can also be viewed as a...

Tuesday saw the market drop to the tune of almost 120 Dow points and nearly 13 S&P points. But market sell-offs aren’t always a bad thing. After all, a pullback can provide a more ideal entry on a desired stock. Thanks to the market rally over the last few weeks, a lot of stocks had...